Gemina Laboratories Ltd. (CSE:GLAB)

Market Cap	3.06M -92.3%
Revenue (ttm)	10.88K
Net Income	-2.93M
EPS	-0.04
Shares Out	76.57M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,000
Average Volume	48,545
Open	0.0600
Previous Close	0.0600
Day's Range	0.0600 - 0.0600
52-Week Range	0.0300 - 1.2500
Beta	-0.34
RSI	28.80
Earnings Date	May 28, 2026

About Gemina Laboratories

Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It also develops respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporated in 2017 and is headquartered in Burnaby, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 6
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: GLAB